Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Search
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Patient Assistance Program
BI Cares Patient Assistance Program Error
Duluth, Georgia
Boehringer Ingelheim Animal Health employs about
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
Biopharma Contract Manufacturing
Biopharma Contract Manufacturing
Our Mission
Our Story
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Shelter Revamps Make for Strong Bonds, More Adoptions
Shelter Revamps Make for Strong Bonds, More Adoptions
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease
Data shows JARDIANCE reduced the risk for new-onset or worsening kidney disease in adults with T2D with established CV disease. View ISI, PI & Med Guide.
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
From Finance to Pharma
From Finance to Pharma
The Research Process
The Research Process
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Our Commitment
Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d
Ridgefield Research and Innovation
Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.